cord
blood
transplant
cbt
cur
mani
primari
immunodefici
pid
associ
risk
viral
infect
graftversushost
diseas
gvhd
serotherapi
reduc
gvhd
potenti
increas
risk
viral
infect
delay
immun
reconstitut
mani
pid
patient
preexist
viral
infect
optim
dose
serotherapi
unclear
perform
retrospect
analysi
consecut
pid
patient
undergo
cbt
compar
immun
reconstitut
viral
infect
gvhd
mortal
longterm
immun
function
highdos
n
lowdos
n
serotherapi
serotherapi
dose
effect
neutrophil
engraft
median
engraft
occur
day
highand
lowdos
serotherapi
respect
lowdos
serotherapi
group
higher
earli
thymic
emigr
count
month
compar
highdos
group
gvhd
sever
number
viral
infect
differ
serotherapi
dose
surviv
transplant
process
highdos
lowdos
group
conclus
lowdos
serotherapi
enhanc
cell
reconstitut
thymopoiesi
first
year
cbt
increas
gvhd
primari
immunodefici
pid
inherit
condit
character
recurr
infect
inflammatori
disord
autoimmun
sever
combin
immunodefici
scid
sever
form
pid
usual
fatal
within
first
year
life
unless
correct
cell
innat
immun
defect
excess
morbid
mortal
childhood
earli
adulthood
hematopoiet
stem
cell
transplant
hsct
cur
mani
patient
surviv
hlamatch
sibl
hsct
scid
tenyear
surviv
nonscid
pid
hlamatch
sibl
hsct
surviv
rate
improv
time
umbil
cord
blood
offer
altern
sourc
stem
cell
transplant
cord
blood
transplant
cbt
match
sibl
donor
unavail
advantag
disadvantag
cbt
bone
marrow
transplant
bmt
peripher
blood
stem
cell
pbsc
review
detail
elsewher
advantag
includ
easi
access
cord
blood
unit
therefor
earlier
transplant
absenc
risk
donor
lower
risk
latent
viral
transmiss
graftversushost
diseas
gvhd
higher
chanc
match
rare
hla
haplotyp
howev
stem
cell
dose
often
low
unrel
donor
avail
boost
hsct
cord
blood
unit
virolog
often
show
slower
engraft
due
lower
dose
compar
bmt
pbsc
factor
increas
risk
preexist
infect
cbt
pid
patient
evid
effect
cbt
pid
come
singl
center
multicent
studi
recent
studi
demonstr
lower
rate
grade
ii
iv
gvhd
improv
surviv
unrel
cbt
author
compar
result
similar
studi
bmt
pid
mortal
associ
preexist
infect
condit
hla
mismatch
underli
diseas
howev
studi
provid
data
lymphocyt
reconstitut
longterm
graft
function
studi
limit
data
lymphocyt
reconstitut
show
absolut
lymphocyt
count
increas
month
proport
increas
cell
month
post
cbt
agerel
normal
valu
reach
month
patient
studi
surviv
patient
seri
independ
intraven
immunoglobulin
respond
cell
stimul
tetanu
hepat
b
vaccin
serotherapi
form
alemtuzumab
b
cell
deplet
human
monoclon
antibodi
ad
condit
regimen
reduc
incid
gvhd
immun
reconstitut
delay
alemtuzumab
patient
malign
nonmalign
hematolog
condit
studi
suggest
slower
immun
reconstitut
higher
dose
use
slower
immun
reconstitut
turn
associ
increas
incid
viral
reactiv
notabl
cytomegaloviru
adenoviru
respiratori
virus
particularli
pertin
consid
cbt
pid
mani
patient
activ
latent
viral
infect
time
hsct
cbt
consid
slower
immun
reconstitut
virolog
role
serotherapi
cbt
pid
explor
date
report
result
retrospect
studi
effect
alemtuzumabbas
serotherapi
dose
regimen
lymphocyt
reconstitut
gvhd
viral
infect
mortal
pid
patient
underw
cbt
intern
center
thirtyfour
consecut
patient
underw
cbt
pid
may
decemb
children
bmt
unit
newcastl
upon
tyne
hospit
nh
foundat
trust
unit
kingdom
identifi
unit
databas
retrospect
studi
patient
perform
previous
report
systemat
chang
serotherapi
polici
children
bmt
unit
alemtuzumab
dose
reduc
determin
protect
effect
gvhd
without
increas
viral
infect
two
patient
exclud
analysi
receiv
alemtuzumab
condit
week
cbt
anoth
exclud
patient
receiv
rabbit
antithymocyt
globulin
atg
instead
alemtuzumb
receiv
serotherapi
n
also
exclud
receiv
chemotherapeut
condit
other
select
group
base
clinic
present
remain
patient
retrospect
nonrandomli
assign
highdos
alemtuzumab
mgkg
given
divid
dose
day
day
day
n
lowdos
alemtuzumab
mgkg
given
divid
dose
consecut
day
day
day
n
serotherapi
group
purpos
analysi
alemtuzumab
pharmacokinet
studi
perform
underli
diagnos
serotheraphi
group
shown
supplementari
tabl
search
suitabl
umbil
cord
donor
unit
initi
match
sibl
cord
store
match
sibl
donor
unavail
transplant
characterist
summar
tabl
hla
match
base
lowresolut
molecular
class
highresolut
molecular
class
ii
type
hla
loci
previous
describ
patient
condit
accord
european
blood
bone
marrow
transplant
group
ebmt
guidelin
ebmt
work
parti
inborn
error
clinic
condit
receiv
either
myeloabl
condit
busulphan
mgkg
cyclophosphamid
mgkg
treosulphan
gm
cyclophosphamid
mgkg
n
reducedintens
condit
treosulphan
gm
fludarabin
mgm
fludarabin
mgm
melphalan
mgm
n
patient
also
receiv
either
highdos
lowdos
serotherapi
part
condit
regimen
alloc
describ
cord
blood
unit
transfus
day
median
nucleat
cell
count
cellskg
rang
median
count
cellskg
rang
patient
nurs
hepafilt
cubicl
patient
receiv
cyclosporin
gvhd
prophylaxi
cotrimoxazol
pneumocysti
jiroveci
prophylaxi
liposom
amphotericin
antifung
prophylaxi
aciclovir
antivir
prophylaxi
patient
receiv
blood
platelet
support
granulocyt
coloni
stimul
factor
engraft
discret
manag
physician
parent
gave
written
consent
accord
local
centr
european
blood
marrow
transplant
guidelin
time
neutrophil
third
consecut
day
absolut
neutrophil
count
anc
l
platelet
platelet
count
l
independ
transfus
support
lymphocyt
first
day
count
cellsml
engraft
record
lymphocyt
subset
analysi
measur
flow
cytometri
previous
describ
briefli
lymphocyt
surfac
marker
studi
perform
fresh
whole
blood
collect
edta
use
appropri
marker
percp
fitc
apc
pe
apc
pe
pe
fitcigm
apcigd
pe
becton
dickinson
uk
ltd
oxford
analyz
becton
dickinson
fac
calibur
flow
cytomet
marker
use
surrog
earli
thymic
emigr
equival
ete
lymphocyt
subset
natur
killer
nk
cell
ete
month
followup
record
specif
antibodi
respons
pneumococc
polysaccharid
prevenar
tetanu
toxoid
haemophilu
influenza
b
vaccin
antigen
measur
elisa
defin
present
absent
vaccin
whole
blood
stain
micro
bead
cell
line
separ
use
automac
autom
benchtop
magnet
cell
sorter
miltenyi
biotec
ltd
surrey
uk
chimer
measur
sexmismatch
case
xyfluoresc
insitu
hybrid
fish
use
standard
cytogenet
techniqu
briefli
interphas
fish
perform
use
vysi
cep
xcep
probe
set
accord
manufactur
protocol
donor
recipi
sex
chimer
measur
short
tandem
repeat
marker
analysi
genom
dna
previous
describ
recent
donor
chimer
cell
b
cell
myeloid
lineag
record
chimer
defin
donor
donor
cell
highlevel
mix
donor
cell
mix
donor
cell
recipi
donor
cell
specif
cell
lineag
patient
consid
viral
infect
posit
virolog
result
pcr
tissu
cultur
electron
microscopi
immunochromogen
method
present
viral
pcr
adenoviru
cytomegaloviru
human
herp
viru
epsteinbarr
viru
enteroviru
parainfluenza
viru
respiratori
syncyti
viru
coronaviru
astroviru
varicellazost
viru
noroviru
electron
microscopi
small
round
structur
viru
coronaviru
noroviru
astroviru
rotaviru
tissu
cultur
polioviru
vaccin
strain
immunochromogen
method
adenoviru
rotaviru
undertaken
newcastl
health
protect
agenc
laboratori
newcastl
unit
kingdom
viral
infect
consid
clear
first
consecut
neg
virolog
result
recurr
infect
later
date
treat
failur
clear
viru
viral
infect
consid
present
patient
die
recent
result
posit
still
virolog
evid
infect
last
followup
gvhd
grade
target
organ
whether
acut
chronic
record
gvhd
defin
modifi
glucksberg
criteria
time
death
caus
death
record
transplantationrel
mortal
trm
defin
caus
death
direct
result
transplant
procedur
time
recent
followup
independ
replac
immunoglobulin
record
supplementari
tabl
differ
highand
lowdos
serotherapi
analyz
fisher
exact
mannwhitney
u
test
perform
use
sa
window
sa
institut
inc
cari
nc
kaplanmei
surviv
analysi
confid
interv
logrank
test
perform
use
spss
statist
ibm
spss
armonk
ny
test
consid
statist
signific
p
demograph
transplant
characterist
summar
tabl
patient
month
age
younger
transplant
year
transplant
significantli
differ
highdos
lowdos
serotherapi
group
p
lowdos
serotherapi
cbt
occur
wherea
highdos
serotherapi
cbt
mainli
occur
consist
systemat
chang
practic
neutrophil
engraft
similar
highand
lowdos
serotherapi
p
median
engraft
occur
day
rang
day
rang
respect
platelet
engraft
occur
median
day
rang
day
rang
highand
lowdos
serotherapi
group
respect
p
platelet
engraft
took
day
patient
highdos
serotherapi
group
lymphocyt
engraft
occur
median
time
day
rang
day
rang
highand
lowdos
serotherapi
respect
p
lymphocyt
count
increas
throughout
first
month
post
cbt
across
differ
lymphocyt
subset
tabl
figur
reconstitut
similar
month
highand
lowdos
serotherapi
group
lymphocyt
subset
month
lowdos
serotherapi
group
significantli
higher
ete
count
compar
highdos
group
p
p
p
respect
ete
reconstitut
follow
similar
trend
reconstitut
figur
month
ete
cell
reconstitut
highdos
group
similar
lowdos
group
lymphocyt
reconstitut
similar
highand
lowdos
serotherapi
group
throughout
first
month
cbt
b
lymphocyt
count
show
trend
increas
number
first
month
post
cbt
highand
lowdos
serotherapi
signific
differ
b
cell
reconstitut
highand
lowdos
serotherapi
group
tabl
figur
nk
cell
count
significantli
higher
month
p
highdos
serotherapi
compar
lowdos
serotherapi
month
signific
differ
nk
cell
count
serotherapi
group
tabl
figur
seven
patient
least
viral
infect
time
cbt
patient
contract
least
viral
infect
post
transplant
patient
achiev
clearanc
viru
patient
insuffici
data
determin
achiev
viral
clearanc
differ
number
viral
infect
present
cbt
new
viral
infect
cbt
highand
lowdos
serotherapi
group
evalu
patient
receiv
serotherapi
clear
viral
infect
tabl
insuffici
result
analyz
time
viral
clearanc
signific
differ
donor
chimer
highdos
lowdos
serotherapi
cell
lineag
figur
one
patient
chronic
granulomat
diseas
receiv
highdos
serotherapi
undergon
second
hsct
fall
myeloid
chimer
except
patient
discontinu
replac
immunoglobulin
month
vaccin
respond
haemophilu
influenza
b
tetanu
toxoid
pneumococc
vaccin
tabl
two
patient
receiv
highdos
serotherapi
depend
immunoglobulin
therapi
month
sinc
made
good
respons
primari
vaccin
one
patient
lowdos
serotherapi
group
mannwhitney
u
p
valu
state
differ
highand
lowdos
serotherapi
consid
signific
p
discontinu
immunoglobulin
yet
receiv
primari
vaccin
eight
patient
develop
acut
gvhd
grade
ii
gvhd
patient
experienc
grade
iv
gvhd
statist
signific
differ
sever
gvhd
highand
lowdos
serotherapi
group
p
tabl
one
patient
receiv
highdos
serotherapi
develop
chronic
skin
gvhd
trm
occur
within
month
transplant
one
patient
receiv
highdos
chemotherapi
die
trm
possibl
venoocclus
diseas
gastrointestin
hemorrhag
complic
chronic
lung
diseas
anoth
patient
receiv
highdos
serotherapi
die
sudden
infant
death
syndrom
classifi
trm
cumul
surviv
trm
highdos
lowdos
serotherapi
group
confid
interv
respect
differ
surviv
group
p
figur
nk
b
cell
reconstitut
demonstr
occur
earli
cbt
wherea
low
cell
number
demonstr
remain
first
month
post
cbt
increas
potenti
risk
viral
infect
compar
bmt
pbsc
give
lymphocyte
deplet
serotherapi
gvhd
prophylaxi
prolong
lymphopenia
post
transplant
give
high
dose
increas
risk
viral
infect
studi
lower
dose
serotherapi
improv
lymphocyt
reconstitut
better
thymopoiesi
month
post
transplant
highdos
serotherapi
particularli
pertin
set
cbt
pid
studi
major
patient
scid
therefor
delay
cell
reconstitut
excess
serotherapi
might
delay
clearanc
preexist
viral
infect
delay
immun
reconstitut
highand
lowdos
serotherapi
could
explain
prolong
exposur
graft
lympholyt
antibodi
higher
dose
given
lympholyt
concentr
alemtuzumab
shown
present
day
hsct
high
dose
given
vivo
recent
prospect
seri
pediatr
patient
underw
cbt
malign
nonmalign
diseas
without
serotherapi
condit
show
earli
restor
lymphocyt
within
first
month
post
cbt
thymic
independ
pathway
produc
effect
viral
specif
cell
thymopoiesi
evid
year
transplant
contrast
studi
chiesa
et
al
studi
demonstr
delay
restor
median
cell
count
month
post
cbt
lowdos
serotherapi
given
delay
lymphocyt
reconstitut
month
post
cbt
use
high
dose
serotherapi
reconstitut
studi
improv
month
lowdos
serotherapi
given
compar
highdos
serotherapi
like
caus
correspond
improv
ete
count
lowdos
serotherapi
group
evid
thymopoiesi
lowdos
serotherapi
group
month
contrast
studi
chiesa
et
al
cell
reconstitut
lowdos
serotherapi
group
seen
studi
month
post
transplant
therefor
like
explain
expans
thymic
depend
independ
manner
patient
studi
experienc
much
lower
rate
acut
gvhd
studi
chiesa
et
al
grade
ii
iv
acut
gvhd
versu
though
may
confound
inclus
patient
malign
diseas
latter
studi
found
protect
afford
gvhd
lower
dose
serotherapi
similar
highdos
serotherapi
studi
chiesa
et
al
patient
viral
infect
patient
die
viral
infect
studi
patient
preexist
viral
infect
develop
new
viral
infect
cbt
differ
highand
lowdos
serotherapi
group
import
pid
set
mani
patient
present
preexist
viral
ill
howev
definit
viral
clearanc
small
number
patient
viral
infect
time
transplant
make
difficult
determin
effect
serotherapi
dose
clearanc
preexist
viral
infect
influenc
give
serotherapi
viral
clearanc
context
pid
cbt
need
work
larger
studi
singl
multicent
studi
cbt
pid
tend
use
standard
dose
atg
serotherapi
knutsen
et
al
demonstr
patient
cell
immunodefici
receiv
dose
atg
mgkgday
day
lymphocyt
number
increas
month
evid
thymopoiesi
use
presenc
cell
marker
month
evid
thymopoiesi
occur
later
demonstr
lowdos
serotherapi
group
studi
overal
studi
demonstr
higher
rate
gvhd
grade
ii
iv
studi
howev
rate
gvhd
like
caus
greater
number
cbt
mismatch
hla
loci
compar
studi
differ
serotherapi
use
combin
use
atg
rather
alemtuzumab
make
direct
comparison
studi
difficult
current
limit
data
regard
cell
function
post
cbt
prolif
respons
mitogen
viralspecif
cell
function
demonstr
earli
month
post
cbt
cell
receptor
repertoir
shown
skew
distribut
year
post
cbt
increas
divers
compar
bmt
recipi
year
post
hsct
current
studi
show
clinic
good
longterm
immun
function
independ
immunoglobulin
replac
year
post
cbt
respons
primari
vaccin
independ
serotherapi
dose
studi
howev
limit
look
numer
function
immun
reconstitut
analysi
effect
serotherapi
cell
function
reconstitut
merit
work
studi
limit
compar
highand
lowdos
serotherapi
regimen
comparison
made
patient
receiv
serotherapi
part
condit
regimen
patient
receiv
serotherapi
preselect
base
poor
clinic
condit
time
transplant
mani
receiv
chemotherapeut
condit
either
receiv
serotherapi
receiv
match
sibl
donor
cbt
factor
differ
significantli
high
lowdos
serotherapi
group
lowdos
serotherapi
cbt
occur
recent
due
systemat
chang
serotherapi
polici
unit
would
allow
introduct
uptod
support
measur
lowdos
serotherapi
group
potenti
influenc
surviv
immun
reconstitut
result
show
lowdos
serotherapi
improv
speed
immun
reconstitut
thymopoiesi
first
year
cbt
without
increas
incid
gvhd
compar
high
dose
serotherapi
result
also
demonstr
lower
rate
gvhd
studi
extent
give
serotherapi
affect
risk
delay
viral
clearanc
unclear
current
studi
research
need
